Are Continuous Glucose Monitors Useful If You Don’t Have Diabetes?

CGMs can show exactly how your glucose changes after meals, exercise, and sleep but more data does not automatically mean better health.

By Practical Health Science Editorial Team Sep 3, 2026 9 min read
Evidence Strength
Limited

This rating reflects the overall strength and consistency of the available evidence.

Are Continuous Glucose Monitors Useful If You Don’t Have Diabetes?
Quick Answer

A continuous glucose monitor can provide interesting and potentially useful information if you do not have diabetes but there is not yet strong evidence that routinely wearing one makes healthy people healthier.

CGMs can show how glucose changes after meals, exercise, sleep, and other daily behaviors. Some small randomized trials suggest that real-time glucose feedback combined with nutrition counseling may help people with overweight, obesity, or prediabetes improve eating behavior, weight, or glucose-related measures.

But that is different from showing that CGM use benefits healthy people with normal glucose regulation.

The American Diabetes Association's 2026 Standards of Care state that there is currently insufficient evidence to use CGM for screening or diagnosing prediabetes or diabetes. Reviews focused specifically on people without diabetes similarly conclude that evidence for broad health or wellness use remains inconsistent and low quality.

There is another important issue:

A glucose rise after eating is not automatically unhealthy.

Even people with normal glucose regulation can temporarily exceed commonly marketed glucose thresholds.

So CGMs may be most useful as a data and behavior feedback tool, particularly for selected higher-risk individuals not as a universal metabolic-health requirement.

What the Science Says

Continuous glucose monitors measure glucose in interstitial fluid, rather than directly measuring blood glucose with every reading.

They provide repeated glucose measurements throughout the day, creating a detailed picture of how glucose changes after food, exercise, sleep, stress, and other behaviors.

That technology has clear clinical value in diabetes, particularly when glucose readings directly guide insulin treatment or help prevent dangerous hypo- or hyperglycemia.

Using the same technology in someone without diabetes is a different scientific question.

The value proposition is usually:

CGM data → identify glucose responses → change behavior → improve metabolic health → reduce future disease risk.

The first step is clearly possible.

The remaining steps are much less established.

A 2024 review specifically examining CGM use in people without diabetes found insufficient high-quality evidence demonstrating reliable detection of clinically meaningful abnormalities, sustained behavior change, or improved metabolic health in otherwise healthy populations.

Evidence appears somewhat more promising in people with prediabetes, obesity, or other elevated metabolic risk, but even there larger and longer randomized trials are needed. A 2025 review concluded that there was not yet strong evidence supporting widespread CGM implementation among people merely at risk of diabetes.

A Glucose “Spike” Is Not Automatically a Sign of Poor Metabolic Health

Consumer CGM platforms often focus heavily on keeping glucose curves as flat as possible.

But human glucose physiology is not supposed to be perfectly flat.

When carbohydrates are digested, glucose enters the circulation. Insulin increases, tissues take up glucose, and glucose concentrations subsequently fall.

Healthy people therefore experience post-meal glucose excursions.

A multicenter study of 153 healthy people without diabetes found an average sensor glucose of approximately 98–99 mg/dL in most age groups.

Participants spent a median:

  • 96% of the day between 70 and 140 mg/dL

  • approximately 30 minutes per day above 140 mg/dL

  • approximately 15 minutes per day below 70 mg/dL

despite being healthy and nondiabetic.

More recent data demonstrate even wider physiological variation.

In the Framingham Heart Study, 560 people classified as normoglycemic spent an average of about:

  • 87% of the day between 70 and 140 mg/dL

  • 12% of the day above 140 mg/dL

  • roughly 15 minutes per day above 180 mg/dL

despite not meeting conventional criteria for prediabetes or diabetes.

That does not mean large glucose excursions are irrelevant.

Higher average glucose and greater glycemic variability can correlate with poorer metabolic health.

But it does mean that:

“My glucose briefly went above 140 mg/dL after eating” is not equivalent to “this meal damaged my metabolism.”

There is currently no universally accepted CGM definition of ideal normoglycemia in people without diabetes.


Can CGM Feedback Actually Change Behavior?

This is arguably the strongest case for CGM use outside diabetes.

Seeing physiological feedback in real time can make an abstract concept concrete.

Instead of being told that walking after dinner may influence glucose, a person can observe the difference on their own glucose trace.

Some trials suggest that this feedback can help.

In a randomized trial involving 40 young adults with overweight or obesity but without diabetes, both groups received education about low-glycemic-index and low-glycemic-load diets.

Only the intervention group also received real-time CGM feedback.

After eight weeks, the CGM group showed greater improvements in several measures including body weight, body fat, fasting glucose, HbA1c, and blood lipids.

Another randomized dietary intervention published in 2025 used flash CGM data to personalize nutrition counseling in adults with obesity.

Participants receiving personalized feedback showed improvements in body weight, abdominal fat, dietary intake, and several metabolic measures relative to controls.

Small randomized studies in people with prediabetes have also found that adding visible CGM feedback to individualized nutrition therapy can improve glucose metrics and some dietary behaviors.

These studies are encouraging.

But they do not prove that simply buying a CGM and watching glucose numbers produces the same benefits.

The intervention often includes:

CGM + dietitian + education + goal setting + repeated counseling.

CGM may be helping people engage with an already effective lifestyle intervention rather than functioning as an independent treatment.


Who Is Most Likely to Benefit?

The strongest rationale is probably not in already healthy people with consistently normal metabolic markers.

It is in people occupying the space between obvious metabolic health and established diabetes.

Examples may include people with:

  • prediabetes

  • overweight or obesity

  • strong family history of type 2 diabetes

  • metabolic syndrome

  • impaired glucose tolerance

  • certain endocrine disorders

  • metabolic dysfunction-associated steatotic liver disease

  • high risk of medication-induced hyperglycemia

A 2025 review evaluating CGM in people at elevated risk of diabetes described promising results in several such populations.

But the authors still concluded that current evidence does not support global CGM implementation for everyone at increased diabetes risk.

Importantly, CGM should also not currently replace established diagnostic testing.

The ADA continues to recommend:

  • fasting plasma glucose

  • HbA1c

  • or a 75-g oral glucose tolerance test

for screening and diagnosis of prediabetes and type 2 diabetes.

Its 2026 Standards explicitly state that evidence remains insufficient to use CGM for that purpose.

So if a consumer CGM repeatedly displays unusual glucose values, the appropriate conclusion is not necessarily:

“The CGM diagnosed insulin resistance.”

It may instead be:

“This pattern may justify conventional clinical testing.”


More Metabolic Data Can Also Create More Anxiety

There is another side to continuous monitoring that receives much less attention.

Providing someone with hundreds of glucose measurements every day creates many opportunities to classify normal biological variation as abnormal.

This may encourage useful experimentation.

It can also encourage unnecessary restriction.

A 2025 mixed-methods study involving CGM users who were not using insulin found that most participants reported positive dietary or physical-activity changes.

But psychological responses varied considerably.

More than two-thirds reported fear of type 2 diabetes when seeing elevated glucose values, and some users experienced distress related to their glucose readings. Greater eating-disorder symptoms were also associated with certain forms of CGM-related distress.

The study was small and cross-sectional, so it cannot show that CGMs caused those psychological effects.

But the concern is plausible.

A person could begin avoiding nutritious foods such as:

  • fruit

  • beans

  • whole grains

  • or other carbohydrate-containing foods

simply because they produce a visible glucose rise.

That would confuse a short-term biomarker response with overall nutritional quality.

The expert community also does not yet completely agree on how abnormal CGM traces should be interpreted in people without diabetes.

A recent study asked 18 CGM experts to independently interpret potentially unusual glucose reports from individuals without diabetes. There was substantial variation in whether clinicians recommended follow-up—even when HbA1c and fasting glucose were normal.

If experts do not yet have standardized interpretation rules, consumers should be cautious about assigning medical meaning to every glucose excursion shown by an app.

Limitations Summary

Several evidence gaps prevent strong conclusions about CGM use in people without diabetes.

First, much of the evidence comes from observational studies.

These studies can show that people with greater glucose variability often have less favorable metabolic profiles, but they cannot establish that reducing those CGM excursions will prevent disease.

Second, randomized trials are generally small and short.

They also frequently combine CGM with dietary counseling, lifestyle education, goal setting, or smartphone coaching.

That makes it difficult to determine whether CGM itself provides the benefit.

Third, different studies use different thresholds.

A glucose level above 140 mg/dL may be labeled a “spike” in one context, while another analysis focuses on 180 mg/dL or measures glucose variability instead.

There are no widely validated consumer targets defining the optimal glucose curve for healthy people.

Fourth, CGM measures interstitial glucose rather than direct venous plasma glucose. Sensor error, physiological lag, compression during sleep, and other technical factors can occasionally produce readings that do not perfectly represent circulating glucose.

Finally, almost no evidence demonstrates that CGM-guided glucose optimization in healthy adults prevents:

type 2 diabetes
cardiovascular disease
dementia
cancer
or premature death

over many years.

The absence of those data is particularly important when wellness marketing implies long-term disease prevention.

What This Means in Real Life

For someone with established diabetes, CGM can be a medically important tool.

For someone without diabetes, its role is very different.

CGM may be reasonably useful if:

You have elevated metabolic risk and want to understand how food, exercise, and daily routines affect glucose.

You are using the data as part of a structured lifestyle program rather than trying to optimize individual glucose numbers in isolation.

Or you are using the sensor temporarily as an educational experiment rather than assuming lifelong monitoring is necessary.

CGM is probably less useful if:

Your HbA1c, fasting glucose, body weight, blood pressure, lipids, exercise habits, and overall metabolic health are already good—and the sensor primarily makes you worry about normal fluctuations.

A useful response to CGM information might be:

“A short walk after this meal improves my glucose profile, and walking is beneficial anyway.”

A less useful response might be:

“My glucose reached 145 mg/dL, so I should never eat fruit again.”

The first uses CGM as feedback.

The second treats a consumer metric as a disease endpoint.

In the United States, the distinction has become especially relevant because OTC access has expanded rapidly.

In March 2024, the FDA cleared the Dexcom Stelo as the first over-the-counter CGM. It was specifically cleared for adults who do not use insulin, including people without diabetes who want to understand how diet and exercise affect their glucose.

Abbott's Lingo and Libre Rio systems also subsequently received FDA clearance for over-the-counter glucose monitoring.

But regulatory clearance means the device can legally be marketed for its intended use.

It does not establish that healthy people who optimize every glucose excursion will experience longer lives or fewer chronic diseases.

Key Takeaway

CGMs can provide useful metabolic information without diabetes—but usefulness depends on what you do with the information and why you are collecting it.

The technology clearly shows individual glucose responses and may help motivate lifestyle changes, particularly in people with obesity, prediabetes, or other metabolic risk factors.

But for metabolically healthy adults, there is currently no strong evidence that routinely wearing a CGM improves long-term health.

And normal post-meal glucose rises should not automatically be treated as pathological “spikes.”

The best current interpretation is:

CGMs are powerful measurement tools. In people without diabetes, they are not yet proven universal health-improvement tools.

Sources

2. Diagnosis and Classification of Diabetes: Standards of Care in Diabetes-2026
American Diabetes Association Professional Practice Committee for Diabetes. Diabetes Care. 2026.
Clinical Guideline DOI: 10.2337/dc26-S002 PMID: 41358893

Provides the current ADA position on diabetes and prediabetes screening. Critically, the guideline states that there is insufficient evidence to support CGM for screening or diagnosis of prediabetes or diabetes.

Innovative solution or cause for concern? The use of continuous glucose monitors in people not living with diabetes: A narrative review
Zhanna Oganesova, John Pemberton, Adrian Brown. Diabetic Medicine. 2024.
Systematic Review DOI: 10.1111/dme.15369 PMID: 38925143

Directly evaluates the evidence supporting CGM use in people without diabetes for detection of abnormal glucose, behavioral change, and metabolic-health improvement. Concludes that consistent high-quality evidence supporting broad wellness claims is lacking.

Continuous Glucose Monitoring in People at High Risk of Diabetes and Dysglycaemia: Transforming Early Risk Detection and Personalised Care
Alexandros L Liarakos, Grigorios Panagiotou, Maria Chondronikola, Emma G Wilmot. Life. 2025.
Systematic Review DOI: 10.3390/life15101579 PMID: 41157252

Evaluates CGM use in people at increased diabetes risk, including obesity and prediabetes. Finds promising applications in selected populations but insufficient evidence for widespread implementation or CGM-based diagnosis.

Defining Continuous Glucose Monitor Time in Range in a Large, Community-Based Cohort Without Diabetes
Nicole L Spartano, Naznin Sultana, Honghuang Lin, Huimin Cheng, Sophia Lu, David Fei, Joanne M Murabito, Maura E Walker, Howard A Wolpert, Devin W Steenkamp. The Journal of Clinical Endocrinology & Metabolism. 2025.
Observational Study DOI: 10.1210/clinem/dgae626 PMID: 39257191

Establishes contemporary reference CGM patterns in normoglycemia, prediabetes, and diabetes. Demonstrates that people with normal conventional glucose status can spend meaningful periods above commonly used consumer glucose thresholds.

Continuous Glucose Monitoring Profiles in Healthy Nondiabetic Participants: A Multicenter Prospective Study
Viral N Shah, Stephanie N DuBose, Zoey Li, Roy W Beck, Anne L Peters, Ruth S Weinstock, Davida Kruger, Michael Tansey, David Sparling, Stephanie Woerner, Francesco Vendrame, Richard Bergenstal, William V Tamborlane, Sara E Watson, Jennifer Sherr. The Journal of Clinical Endocrinology & Metabolism. 2019.
Other DOI: 10.1210/jc.2018-02763 PMID: 31127824

Provides CGM reference values in healthy individuals across a wide age range and demonstrates that temporary readings above 140 mg/dL or below 70 mg/dL can occur even in people without diabetes.

Utilising a Real-Time Continuous Glucose Monitor as Part of a Low Glycaemic Index and Load Diet and Determining Its Effect on Improving Dietary Intake, Body Composition and Metabolic Parameters of Overweight and Obese Young Adults: A Randomised Controlled
Khadidja Chekima, Mohd Ismail Noor, Yasmin Beng Houi Ooi, See Wan Yan, Mohammad Jaweed, Brahim Chekima. Foods. 2022.
Randomized Controlled Trial DOI: 10.3390/foods11121754 PMID: 35741952

Demonstrates potential benefit from adding real-time CGM feedback to dietary education in young adults with overweight or obesity but without diabetes. Supports potential behavioral utility while not establishing benefit in metabolically healthy adults.

Application of personalized nutrition counseling according to glycemic response in obese adults: A randomized dietary intervention study
Jooeun Kim, Mihee Kang, Kwangho Song, Hyejin Ahn, Yoo Kyoung Park. Nutrition. 2025.
Randomized Controlled Trial DOI: 10.1016/j.nut.2024.112641 PMID: 39705786

Evaluates personalized nutrition counseling incorporating flash CGM data in adults with obesity. Reported improvements in weight, body composition, dietary behavior, and selected metabolic markers.

Understanding the benefits and psychological burdens of using continuous glucose monitoring for lifestyle change: A mixed-methods cross-sectional study
Kelli M Richardson, Michelle R Jospe, Jessie Somerville, Julia Felrice, Susan M Schembre. Obesity Research & Clinical Practice. 2025.
Mechanistic Study DOI: 10.1016/j.orcp.2025.10.003 PMID: 41102072

Provides evidence concerning both perceived behavior-change benefits and potential psychological distress associated with CGM use outside intensive insulin management. Particularly relevant to concerns about fear of glucose excursions and relationships with food.

Expert Clinical Interpretation of Continuous Glucose Monitor Reports From Individuals Without Diabetes
Nicole L Spartano, Brenton Prescott, Maura E Walker, Eleanor Shi, Guhan Venkatesan, David Fei, Honghuang Lin, Joanne M Murabito, David Ahn, Tadej Battelino, Steven V Edelman, G Alexander Fleming, Guido Freckmann, Rodolfo J Galindo, Michael Joubert, M Cecilia Lansang, Julia K Mader, Boris Mankovsky, Nestoras N Mathioudakis, Viswanathan Mohan, Anne L Peters, Viral N Shah, Elias K Spanakis, Kayo Waki, Eugene E Wright, Mihail Zilbermint, Howard A Wolpert, Devin W Steenkamp. Journal of Diabetes Science and Technology.. 2026.
Expert Review DOI: 10.1177/19322968251315171 PMID: 39936548

Demonstrates the current lack of standardized clinical interpretation for unusual CGM patterns in people without diabetes. Even expert clinicians showed incomplete agreement about when CGM findings warranted further clinical evaluation.

FDA Clears First Over-the-Counter Continuous Glucose Monitor.
U.S. Food and Drug Administration.. U.S. Food and Drug Administration. 2024.
Regulatory Document

Documents FDA clearance of Dexcom Stelo as the first OTC CGM for adults who do not use insulin, including people without diabetes seeking information about glucose responses to diet and exercise. Important for distinguishing regulatory access from demonstrated long-term clinical benefit.

Medical disclaimer: This article is for educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a qualified healthcare professional for personal medical decisions.

More from Metabolic Health

Explore more Practical Health Science articles from this category.

Metabolic Health Myth Check Evidence: Moderate

Do Food Cravings Mean You’re Deficient in a Nutrient?

Social media often claims that specific food cravings reveal specific nutrient deficiencies. The biology is more complicated. Here’s what the evidence says about cravings for sugar, salt, chocolate, and carbs.

Practical Health Science Editorial Team 7 min read Sep 6, 2026
Metabolic Health Myth Check Evidence: Moderate

Do Artificial Sweeteners Spike Insulin or Cause Weight Gain?

Artificial and other non-nutritive sweeteners generally do not produce a meaningful acute insulin or glucose spike on their own. They may modestly help with weight control when they replace sugar, but long-term observational studies remain harder to interpret.

Practical Health Science Editorial Team 6 min read Sep 4, 2026